JP2012516897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516897A5 JP2012516897A5 JP2011549261A JP2011549261A JP2012516897A5 JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5 JP 2011549261 A JP2011549261 A JP 2011549261A JP 2011549261 A JP2011549261 A JP 2011549261A JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- antibiotic
- composition according
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14995709P | 2009-02-04 | 2009-02-04 | |
| US61/149,957 | 2009-02-04 | ||
| PCT/US2010/023214 WO2010091189A1 (en) | 2009-02-04 | 2010-02-04 | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012516897A JP2012516897A (ja) | 2012-07-26 |
| JP2012516897A5 true JP2012516897A5 (enExample) | 2013-03-21 |
Family
ID=42133763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549261A Pending JP2012516897A (ja) | 2009-02-04 | 2010-02-04 | シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100272736A1 (enExample) |
| EP (1) | EP2393515A1 (enExample) |
| JP (1) | JP2012516897A (enExample) |
| CA (1) | CA2751433A1 (enExample) |
| WO (1) | WO2010091189A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013515079A (ja) | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
| CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| HUE050985T2 (hu) * | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| CN118620074A (zh) * | 2020-06-01 | 2024-09-10 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2024261584A1 (en) * | 2023-06-17 | 2024-12-26 | Abgenics Lifesciences Private Limited | A composition effective against beta-lactam antibiotic-resistant pseudomonas aeruginosa |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0229107A4 (en) * | 1985-06-06 | 1987-11-09 | Genetic Systems Corp | PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO -i(PSEUDOMONAS AERUGINOSA) EXOTOXIN A. |
| NZ218499A (en) * | 1985-12-10 | 1990-04-26 | Genetic Systems Corp | Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods |
| DK172840B1 (da) * | 1986-07-03 | 1999-08-09 | Genetic Systems Corp | Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| WO2000033872A2 (en) | 1998-11-25 | 2000-06-15 | Mcw Research Foundation, Inc. | Method of and compositions for immunization with the pseudomonas v antigen |
| WO2002064161A2 (en) * | 2001-01-26 | 2002-08-22 | Mcw Research Foundation, Inc. | Method and compositions for immunization with the pseudomonas v antigen |
| EP2990053A1 (en) | 2004-01-20 | 2016-03-02 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| PL2343380T3 (pl) | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| CA2957056A1 (en) * | 2006-09-06 | 2008-03-13 | C3 Jian, Inc. | Selectively targeted antimicrobial peptides and the use thereof |
| CA2706732A1 (en) * | 2007-11-30 | 2009-06-11 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
-
2010
- 2010-02-04 CA CA2751433A patent/CA2751433A1/en not_active Abandoned
- 2010-02-04 US US12/700,599 patent/US20100272736A1/en not_active Abandoned
- 2010-02-04 JP JP2011549261A patent/JP2012516897A/ja active Pending
- 2010-02-04 EP EP10704049A patent/EP2393515A1/en not_active Withdrawn
- 2010-02-04 WO PCT/US2010/023214 patent/WO2010091189A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ali et al. | Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults | |
| Sanya et al. | Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections | |
| Reig et al. | What is new in the anti–Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert? | |
| King | Bronchiectasis | |
| Falagas et al. | Tetracyclines for multidrug-resistant Acinetobacter baumannii infections | |
| ES2983252T3 (es) | Tratamiento de las infecciones polibacterianas | |
| Rhodes et al. | Resistance trends and treatment options in gram-negative ventilator-associated pneumonia | |
| JP2012516897A5 (enExample) | ||
| JP2017519768A5 (enExample) | ||
| JP2013515079A5 (enExample) | ||
| JP2021063090A5 (enExample) | ||
| JP2017512193A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JP2016507470A5 (enExample) | ||
| US20220041695A1 (en) | Method for preventing or treating nosocomial pneumonia | |
| Wróblewska | Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art | |
| CN111372603A (zh) | 针对铜绿假单胞菌感染的组合物和方法 | |
| Dunn | Diagnosis and treatment of infection | |
| Okumura et al. | Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: successful treatment with cefuzonam, ampicillin and imipenem | |
| Tur | Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018 | |
| Odland | IDWeek 2019 | |
| Odland | IDWeek 2019. Washington, DC, USA-October 2-6, 2019 | |
| Kokai-Kun et al. | 1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance | |
| Tümmler | aeruginosa [version 1; peer review: 2 approved] |